Our CEO Deana Mohr sat down with Precision Valley to discuss:
Why breaking the silence matters for patients and entrepreneurs
How to tackle challenges when the path isn't clear
What Europe needs to change to compete globally in scaling innovation
Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of cell therapy pioneer Christine Günther, MD, PhD, as Chief Technology Officer (CTO), effective December 1, 2025. Dr. Günther brings more than 30 years of experience translating regenerative medicine innovations from development to clinical application. Dr. Günther
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
